Loading stock data…
$17.09-0.09 (-0.49%)
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer.
Janux Therapeutics, Inc. in the Healthcare sector is trading at $17.09 with a market capitalization of $1.0B. Wall Street consensus targets $36.24 (17 analysts), implying a +112.0% move over the next 12 months. The stock is currently 52% below its 52-week high of $35.34, remaining 13.0% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $10.27M↑ | $3.73M | $0↓ | $10.00M | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$31.69M↑ | -$34.21M↑ | -$42.40M↓ | -$35.25M↑ | -$45.12M |
| Net Income | -$21.97M↑ | -$24.36M↑ | -$31.95M↓ | -$24.31M↑ | -$33.86M |
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technolo...